Matthew Galsky, MD
Medical Oncology · New York, NYNPI 1639140668
Payments from drug & device makers
Across 1,129 payments — averaging $24,872 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$13.6M
- Seagen Inc.$2.9M
- AstraZeneca$2M
- Takeda Pharmaceuticals U.S.A., Inc.$1.9M
- Astellas US Technologies$1.7M
- Genentech, Inc.$1.5M
- plus $4.4M from 28 others
Across 33 payments — averaging $996.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$29K
- F. Hoffmann-la Roche AG$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 248 | $13,608,569 |
| Seagen Inc. | 199 | $2,947,528 |
| AstraZeneca | 61 | $1,974,118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $1,949,539 |
| Astellas US Technologies | 13 | $1,660,119 |
| Genentech, Inc. | 43 | $1,494,503 |
| E.r. Squibb & Sons, L.L.C. | 76 | $1,315,592 |
| Pfizer | 78 | $1,163,063 |
| Eli Lilly | 5 | $729,563 |
| Beigene, Ltd. | 151 | $465,572 |
| Jazz Pharmaceuticals Inc. | 71 | $212,415 |
| GSK | 27 | $129,904 |
| AbbVie | 18 | $126,417 |
| Astellas Pharma Global Development | 11 | $97,471 |
| Taiho Oncology, Inc. | 7 | $40,839 |
| Incyte Corporation | 47 | $38,758 |
| Beigene USA, Inc. | 2 | $28,023 |
| Beone Medicines USA, Inc. | 3 | $27,742 |
| Janssen Global Services, LLC | 13 | $20,434 |
| Gilead | 12 | $13,065 |
| F. Hoffmann-la Roche AG | 8 | $8,528 |
| Novartis | 1 | $7,738 |
| Janssen Research & Development, LLC | 4 | $5,015 |
| EMD Serono, Inc. | 3 | $4,875 |
| Astrazeneca UK Limited | 7 | $4,623 |
| EMD Serono Research & Development Institute, Inc. | 1 | $1,500 |
| Dendreon Pharmaceuticals LLC | 1 | $1,200 |
| Janssen Scientific Affairs, LLC | 2 | $1,048 |
| Daiichi Sankyo Inc. | 1 | $831 |
| Johnson & Johnson | 1 | $620 |
| Samsung Bioepis Co., Ltd. | 1 | $570 |
| Innovation Technologies Inc | 1 | $107 |
| Genentech USA, Inc. | 1 | $99 |
| Tempus AI, Inc | 2 | $38 |
How this compares
$28,080,028 in reported general payments places this provider in the 95th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in New York
- Robert MotzerNew York$32.8M
- Alan HoNew York$32M
- Michael MorrisNew York$30.4M
- Wungki ParkNew York$25.5M
- Komal JhaveriNew York$22.3M
- Joshua RichterNew York$19.9M
- Jia RuanNew York$19.8M
- Andrea CercekNew York$17.8M
- Amy TierstenNew York$17.6M
- Rona YaegerNew York$17.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.